Psoriatic Arthritis News

The FDA has approved Idacio as the eighth biosimilar to adalimumab, for all eligible indications of the reference product, clearing the way for its U.S. release in 2023 alongside a deluge of other Humira biosimilars.

Patients with psoriatic arthritis who receive tofacitinib demonstrate “sustained improvements” in dactylitis compared with those who did not receive tofacitinib, according to data published in BMC Rheumatology.

PHILADELPHIA — Guided online participation in a wellness program was preferred over in-person or self-guided programs among patients with psoriatic arthritis, according to a poster presentation at ACR Convergence 2022.

PHILADELPHIA — The efficacy of COVID-19 vaccinations is similar in patients with psoriatic disease compared non-psoriatic controls, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Despite frequent reports of poor sleep quality among patients with psoriatic arthritis, many do not receive treatment, according to findings from a cross-sectional study reported at ACR Convergence 2022.

PHILADELPHIA — Non-Hispanic white patients are overrepresented while Black and Hispanic patients are underrepresented in pivotal psoriatic arthritic clinical trials, according to data presented at ACR Convergence 2022.

PHILADELPHIA — Making sense of real-world data and black-box warnings associated with Janus kinase inhibitors can be challenging for rheumatologists hoping to prescribe these medications, according to a presenter at ACR Convergence 2022.

PHILADELPHIA — Among patients with psoriatic arthritis, izokibep exhibited clinically significant improvements across various patient reported outcomes, according to findings presented at ACR Convergence 2022.

PHILADELPHIA — Interleukin-17 inhibition with bimekizumab yields strong joint and skin effects up to week 52 in patients with active psoriatic arthritis, according to data presented at ACR Convergence 2022.

PHILADELPHIA — In patients with psoriatic arthritis, upadacitinib showed greater improvement compared with both placebo and adalimumab as assessed by the Routine Assessment of Patient Index Data 3, or RAPID3, scores.